- Infinity Pharmaceuticals (INFI +0.2%) purchases an option to buy out all future royalty payments due to Takeda's Millennium Pharmaceuticals for sales of IPI-145, Infinity's oral PI3K inhibitor.
- In exchange for a one-time upfront payment of $5M, the company receives an option to terminate its obligation to Millennium future royalties related to IPI-145 in oncology. Infinity may exercise the option by providing written notice to Millennium and paying a one-time exercise fee of $52.5M on or before March 31, 2015.
- Infinity will remain obligated to pay Millennium milestones related to the first two distinct PI3K product candidates that gain regulatory approval, including IPI-145. The remaining payments include up to $220M in success-based regulatory milestones, up to $230M in commercial milestones and up to $5M in development milestones.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Tue, 5:41PM)
at Benzinga.com (Jan 12, 2015)
at MarketWatch.com (Jan 8, 2015)
at CNBC.com (Jan 8, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs